# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Judy Garland (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML005-SYN
- Date: 2026-08-31
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Ellsworth-Diaz, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Ten-week review: phenobarbital taper, four weeks after stopping dextroamphetamine. **S**

## History of present illness

Ms. Garland returns six weeks after her four-week review. She took the last dextroamphetamine tablet four weeks ago. For about two weeks afterwards she was tired, slept more and felt flat, and then her energy returned; she has had occasional urges to take a pill before rehearsals and has not acted on them. Her appetite has come back and she eats three meals on most days. She has gained 1.3 kg since the last visit, and she worries about it; we talked about it without a target. The step to 64.8 mg of phenobarbital went smoothly. Two weeks ago, at the sick visit for laryngitis, the next step was paused; her voice recovered within six days and she is back to singing. She sleeps about six hours on most nights. She saw the dietitian last week. Her mood is better. **S**

| Element | Detail |
|---|---|
| Dextroamphetamine | Stopped four weeks ago; two weeks of tiredness, then better |
| Phenobarbital | 64.8 mg a day for four weeks; step paused at the sick visit |
| Laryngitis | Resolved in six days |
| Sleep | About six hours; Insomnia Severity Index 13 |
| Mood | PHQ-9 9; GAD-7 8 |
| Weight | 48.9 kg; three meals on most days |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy back to her usual; no fever |
| Ears, nose, mouth, and throat | Negative | Voice recovered; no sore throat |
| Neurological | Negative | No tremor or seizure-like episodes |
| Psychiatric | Positive | Occasional urges to take a stimulant before rehearsals; mood better; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, one tablet daily **S**
- Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a time **S**
- Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/72 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 48.9 kg; BMI 21.4 kg/m². All vital signs are synthetic.

PHQ-9: 9; GAD-7: 8. All results are synthetic.

## Change since baseline

- PHQ-9: 14 at baseline, 9 at this visit **S**
- GAD-7: 13 at baseline, 8 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 112/72, pulse 72; weight 48.9 kg, BMI 21.4 |
| Ears, nose, mouth, and throat | Voice clear; throat normal |
| Neurological | No tremor or nystagmus |
| Psychiatric | Brighter; no signs of sedation or withdrawal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Barbiturate use disorder on a phenobarbital taper** (F13.20). Stable at 64.8 mg a day after the pause. Safety reviewed: no thoughts of suicide or self-harm; supply locked away. **S**
   - Lower phenobarbital to 56.7 mg a day today (24.3 mg morning, 32.4 mg at bedtime), then 48.6 mg a day in two weeks and 40.5 mg a day at the preventive visit, if she is well.
2. **Stimulant use disorder, mild, in early remission** (F15.10). No stimulant for four weeks after the taper; occasional urges managed with her therapist. Pulse 72 off the stimulant. **S**
   - No stimulant prescriptions; she will tell us if urges grow.
3. **Depression with anxious distress on sertraline** (F32.1). PHQ-9 9 and GAD-7 8, improving through the end of the stimulant. The PHQ-9 was not repeated for six weeks, longer than the monthly check advised in acute treatment; no harm resulted, since her weekly therapist saw no worsening and today's score is lower. **S**
   - Continue sertraline 50 mg daily.
   - PHQ-9 at the preventive visit in four weeks and monthly after that.
4. **Chronic insomnia** (G47.00). Insomnia Severity Index 13 from 21; CBT-I helping. **S**
   - Begin a gentle sleep window of six and a half hours, set with her CBT-I therapist around performances.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Barbiturate dose, adherence, extra doses, and withdrawal signs (tremor, sweating, pulse, sleep, seizure warning signs) | Every visit | Completed today | 64.8 mg a day; no withdrawal signs |
| Medication safety | Taper pace | Reductions of no more than about 20% every two weeks, slower toward the end; pause for symptoms, illness or a major performance | Completed today | 81 to 64.8 mg two weeks after the first step; paused at the sick visit; 64.8 to 56.7 mg today (12.5%) |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's prescriptions; no opioid from the sick visit |
| Laboratory | Urine drug testing, explained as part of care | At the start, after the change to phenobarbital, and periodically during the taper | Up to date | Last at the four-week visit; next at four months |
| Medication safety | Limited dispensing, locked storage and take-back of unused capsules | Seven days at first, then two weeks at a time | Completed today | Two-week supplies; locked box |
| Medication safety | Mood, sleep, energy and appetite after stopping the stimulant | Weekly for the first month after stopping, then each visit | Completed today | Two weeks of tiredness and flat mood, then better; appetite back; occasional urges |
| Examination | Electrocardiogram | Before continuing a stimulant | Not indicated | Stimulant stopped |
| Survey | CBT for insomnia, sleep diary and Insomnia Severity Index | Weekly CBT-I sessions; sleep diary and index at each visit | Completed today | Weekly sessions; Insomnia Severity Index 13 |
| Medication safety | New hypnotic (benzodiazepine, Z-drug, trazodone or antihistamine) | Not recommended as a replacement | Not indicated | No new hypnotic |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Deferred | PHQ-9 9 today, six weeks after the last score, longer than the monthly check advised; the sick visit did not repeat it. No harm resulted: her weekly therapist saw no worsening and today's score is lower. Corrective action: PHQ-9 at the preventive visit and monthly after that |
| Survey | Anxiety (GAD-7) | With each PHQ-9 while anxiety is treated | Completed today | GAD-7 8 |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | 50 mg daily; no side effects |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, means safety and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; the 988 Suicide & Crisis Lifeline in her phone |
| Examination | Weight, meals and disordered-eating screen, without a weight target | Every visit | Completed today | Weight 48.9 kg, BMI 21.4; three meals on most days; discussed without a target |
| Referral | Dietitian visit | Within a month of intake | Completed today | Seen last week by the second dietitian; plan for meals around rehearsals |
| Medication safety | Contraception that phenobarbital does not weaken | Medroxyprogesterone every 13 weeks | Due | Second injection due at the preventive visit in four weeks |
| Medication safety | Naloxone | Reassess at every visit and whenever an opioid is prescribed | Not indicated | No opioids prescribed or used; codeine was avoided at the sick visit |
| Self-management | Alcohol and other sedatives | Every visit | Completed today | No alcohol; no other sedatives or sleep aids |

## Goal progress

- Change from secobarbital to phenobarbital under supervision without a withdrawal seizure or delirium. Outcome by 2026-07-20: Four-day supervised admission; no seizure, delirium or severe withdrawal. **S**
- Lower the phenobarbital dose slowly, at no more than about 20% every two weeks, toward stopping. In progress; target 2026-10-26. **S**
- Stop dextroamphetamine with a short taper and no return to it. Outcome by 2026-08-31: Stopped after a two-week taper; tiredness for about two weeks, then better. **S**
- Sleep six hours or more on most nights using CBT for insomnia. In progress; target 2026-10-26. **S**
- PHQ-9 below 5 by six months. In progress; target 2026-10-26. **S**
- Regular meals and weight she is comfortable with, without dieting drugs. In progress; target 2026-10-26. **S**

## Guideline basis

- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025), American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024), American Society of Addiction Medicine and American Academy of Addiction Psychiatry (Journal of Addiction Medicine)
- Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline (2017), American Academy of Sleep Medicine (Journal of Clinical Sleep Medicine)
- Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016), American College of Physicians (Annals of Internal Medicine)
- U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Prescription Drug Monitoring Programs (PDMPs) (2026), Centers for Disease Control and Prevention
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Nurse phone check before each taper step. Preventive visit in four weeks with the PHQ-9 and the second contraceptive injection. Four-month review in eight weeks with laboratory checks. **S**
- Next scheduled visit 2026-09-28: periodic adult preventive visit. **S**
